ABSI
Absci Corp
NASDAQ · Healthcare · Biotechnology · US
$8.54
+3.52%Year over year
Reported trailing growth
- Revenue
- -62.3%
- EBITDA
- -10.4%
- EBIT
- -11.5%
- EPS
- +14.9%
- Free cash flow
- -42.0%
- Operating cash flow
- -41.5%
Forward estimates
Based on analyst estimates
- Revenue
- +1610.3%
- EBITDA
- +27.1%
- EPS
- +28.2%
Three-year CAGR
- Revenue
- -21.3%
- EBITDA
- -9.6%
- EBIT
- -14.5%
- Net income
- -11.7%
- EPS
- +10.6%
- Free cash flow
- -29.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026